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Aims Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We
investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of
this therapy in patients with renal dysfunction.
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Methods
and results
The FAIR-HF trial randomized 459 CHF patients with iron deficiency (ferritin<100 μg/L, or between 100 and 299 μg/L
if transferrin saturation was <20%): 304 to i.v. ferric carboxymaltose (FCM) and 155 to placebo, and followed-up for
24 weeks. Renal function was assessed at baseline and at weeks 4, 12, and 24, using the estimated glomerular filtration
rate (eGFR, mL/min/1.73m2), calculated from the Chronic Kidney Disease Epidemiology Collaboration (CKD–EPI)
formula. At baseline, renal function was similar between groups (62.4± 20.6 vs. 62.9± 23.4 mL/min/1.73m2, FCM vs.
placebo). Compared with placebo, treatment with FCM was associated with an increase in eGFR [treatment effect:
week 4, 2.11± 1.21 (P = 0.082); week 12, 2.41±1.33 (P = 0.070); and week 24, 2.98± 1.44 mL/min/1.73m2 (P =
0.039)]. This effect was seen in all pre-specified subgroups (P > 0.20 for interactions). No interaction between the
favourable effects of FCM and baseline renal function was seen for the primary endpoints [improvement in Patient
Global Assessment (P = 0.43) and NYHA class (P = 0.37) at 24 weeks]. Safety and adverse event profiles were similar
in patients with baseline eGFR <60 and ≥60 mL/min/1.73m2.
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Conclusions Treatment of iron deficiency in CHF patients with i.v. FCM was associated with an improvement in renal function.
FCM therapy was effective and safe in CHF patients with renal dysfunction.
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Introduction
Renal dysfunction often complicates the natural course of chronic
heart failure (CHF), and cardio-renal interactions are involved
in the pathophysiology of CHF syndrome.1,2 However, there is
*Corresponding author: Department of Heart Diseases, Medical University, Clinical Military Hospital, 53-114 Wrocław, Weigla 5, Poland. Tel: +48 71 7660237, Fax: +48 71
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. no established evidence-based therapy for CHF patients with
cardio-renal syndrome.3
Anaemia and iron deficiency (ID) constitute an important part
of the pathophysiology of cardio-renal syndrome.4,5 In anaemic
patients with chronic kidney disease (CKD), iron repletion
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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is an established part of disease management, resulting in
increased haemoglobin levels, decreased concomitant therapy
with erythropoiesis-stimulating agents, and stabilization of renal
function.6,7 It has also been demonstrated that CHF patients with
anaemia and renal dysfunction may benefit from i.v. iron therapy
with subsequent improvement in renal function.8
The importance of ID in CHF has only recently drawn clinical
attention.9,10 ID is prevalent in CHF, may be present independently
of anaemia, and predicts poor outcome, reduced exercise capacity,
and impaired quality of life.11–15 I.v. iron supplementation in CHF
patients with ID was proven to be well tolerated, resulting in
favourable effects on symptoms, functional status, and quality of
life.8,16–18
Iron is a metabolically active micronutrient involved in numer-
ous biological processes, with a key role in oxygen transportation
and storage, oxidative metabolism, and synthesis and degrada-
tion of lipids, carbohydrates, DNA, and RNA.19,20 Preserved iron
metabolism is particularly important for cells and organs with high
energy demand (e.g. skeletal muscle, kidney, myocardium).19–21
Thus, it can be hypothesized that iron repletion may favourably
affect the function of these organs, in particular kidney function.
On the other hand, there is concern that treatment with i.v. iron
may promote oxidative stress and the proinflammatory response,
leading to renal injury.22
To address these controversies, we assessed the effect of i.v.
iron [with ferric carboxymaltose (FCM)] on renal function in CHF
patients participating in the FAIR-HF (Ferinject® Assessment in
patients with IRon deficiency and chronic Heart Failure) study.16
Additionally, we evaluated the efficacy and safety of i.v. iron in CHF
patients with renal dysfunction.
Methods
Study design
The design, conduct, and principal results of the FAIR-HF study
have been reported elsewhere.16,23 The study complied with the
Declaration of Helsinki and the protocol was approved by local ethics
committees in all centres. In summary, FAIR-HF was a multicentre,
randomized, double-blind, placebo-controlled study which recruited
459 ambulatory patients with CHF in NYHA class II or III, with
LVEF ≤40% (NYHA II) or ≤45% (NYHA III), a screening haemoglobin
between 95 and 135 g/L, and ID defined on the basis of laboratory
assessments when the screening serum ferritin level was <100 μg/L,
or between 100 and 299 μg/L when transferrin saturation (TSAT) was
<20%. The total iron dose required for iron repletion was calculated
at baseline using the Ganzoni formula,24 and patients were randomized
in a 2:1 ratio to receive FCM (Ferinject®, Vifor Pharma, Switzerland;
200mg iron) or saline i.v. weekly until iron repletion (correction phase),
then 4 weekly until week 24 (maintenance phase). Regular assessments
were performed at weeks 4, 12, and 24, and a follow-up visit was
completed at week 26 (or within 2 weeks after the last treatment).23
Renal function assessment
The estimated glomerular filtration rate (eGFR) was the primary
index of renal function. The Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD–EPI) formula25 was used to calculate the
eGFR. Renal function was evaluated at baseline and at weeks 4, ..
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.. 12, and 24. Serum creatinine assessments used for eGFR calcula-
tion were performed at a central laboratory and was standardized
using a Roche Alkaline picrate rate blanked and compensated
methodology. The instrument platform used in the study was from
Roche.
Patients were categorized on the basis of their baseline eGFR
according to the cut-off values used by the National Kidney Foun-
dation for the classification of chronic renal disease:26 preserved
renal function (eGRF ≥60mL/min/1.73m2) and impaired renal function
(<60mL/min/1.73m2).
There was no upper serum creatinine level considered as an exclu-
sion criterion for the study. The primary outcome of this analysis was
the change in eGFR (mL/min/1.73m2) between baseline and weeks 4,
12, and 24. This was a prospectively planned safety endpoint of the
trial.23 Originally, the Modification of Diet in Renal Disease (MDRD)
formula27 was planned to be used for eGFR calculation. In this anal-
ysis, however, we applied the CKD–EPI formula to calculate eGFR
as this formula is more robust and currently recommended, partic-
ularly in patients with systolic CHF.28,29 The MDRD formula was
used for sensitivity analysis. Additionally, we analyzed three categor-
ical changes in eGFR at week 24 defined as: no effect on renal function
(change in eGFR from baseline between –3 and +3mL/min/1.73m2),
improvement (increase in eGFR from baseline >3mL/min/1.73m2),
and deterioration in renal function (decrease in eGFR from baseline
>3mL/min/1.73m2). This outcome was defined retrospectively. For
sensitivity analysis, we also used a relative cut-off level of 5% change
from baseline eGFR
Statistical analysis
Continuous data were described using mean and standard deviation, or
median with 25th and 75th percentiles, depending on the distribution
of the data, and compared between those with or without impaired
renal function using t-tests or Kruskal–Wallis tests, as appropriate.
Categorical data are described using number (percentage) and are
compared between the groups using 𝜒2 tests or Fisher’s exact test
as appropriate. The primary outcome of interest as noted above was
the change from baseline in eGFR at week 24. In addition, we were
also interested in analyzing the original efficacy and safety endpoints
of the trial according to the baseline renal function in the two eGFR
subgroups (<60 and ≥60mL/min/1.73m2). The co-primary endpoints
of the trial were the self-reported Patient Global Assessment (PGA)
and NYHA class (adjusted for baseline class) at week 24.23 Secondary
efficacy endpoints were the PGA and NYHA class at weeks 4 and
12, as well as the 6min walk test distance, the overall Kansas City
Cardiomyopathy Questionnaire (KCCQ) score,30 and the European
Quality of Life–5 Dimensions (EQ-5D) visual analogue scale (VAS)31
at weeks 4, 12, and 24 (all adjusted for baseline values). For both the
overall KCCQ and the EQ-5D VAS, the scores ranged from 0 to 100,
with higher scores indicating better quality of life.30,31 Safety endpoints
included any serious and non-serious adverse events, hospitalization,
and death up to week 26.16,23
For the change in eGFR, comparisons of changes from baseline
at 4, 12, and 24 weeks between the placebo and FCM group were
evaluated by comparing the least square means at each visit from a
repeated-measures model using an unstructured covariance structure
and adjusting for the continuous baseline value and a visit× drug
interaction. Interaction tests for subgroup analysis for the primary
outcome were performed by adding an interaction term between the
pre-specified subgroup and treatment.
For the other continuous endpoints, similar repeated-measures
analyses were performed in subgroups of patients with impaired and
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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preserved renal function, comparing the least square means between
treatment groups at each visit and adjusting for the continuous baseline
value as well as a visit× drug interaction. For categorical endpoints,
including the original co-primary endpoints, differences in the distri-
bution of responses to treatment at each of 4, 12, and 24 weeks in the
two treatment groups were tested by ordered polytomous regression
for impaired and preserved renal function patients separately.32 Odds
ratios (ORs) for the treatment difference at each time point, 95%
confidence intervals (CIs), and corresponding P-values are provided
for each eGFR subgroup. Tests for interaction between impaired and
preserved renal function patients were carried out in a joint model
including all patients. For data on the NYHA class, the model was
adjusted for the baseline value. Cox proportional hazard regression
models for safety outcomes were used to compare the time to first
event using the treatment received, estimating a hazard ratio (HR) for
the FCM compared with placebo plus 95% CIs, and a corresponding
P-value. Event rates using person–time ‘at risk’ denominators are also
provided.
Differences between the percentages of patients withdrawing early
from medication in each group were compared using Fisher’s exact
test. Deaths were analyzed separately. All analyses were conducted
with SAS software, version 9.2 (SAS Institute, Cary, NC, USA).
Results
Characteristics of the study population
by baseline renal function
Baseline characteristics of the FAIR-HF study population have been
previously reported.16 In brief, 459 patients were recruited of
which 304 were randomly assigned to FCM and 155 to placebo.
Baseline clinical and laboratory characteristics and the use of
cardiac medications at the time of enrolment were similar between
the two treatment groups.16
At baseline, mean eGFR was 62.9± 23.4 and 62.4± 20.6mL/
min/1.73m2 in the placebo and FCM groups, respectively; 130
(42.8%) patients in the FCM group and 73 (47.1%) in the placebo
group, respectively, had impaired renal function, as evidenced by
eGFR <60mL/min/1.73m2.
Table 1 presents the baseline demographic and clinical charac-
teristics by baseline renal function. Patients with impaired renal
function tended to be older, with more symptomatic CHF (as
evidenced by higher NYHA class) and more frequent cardio-
vascular risk factors (dyslipidaemia and diabetes mellitus), as
well as a medical history of myocardial infarction and coronary
revascularization. These patients were more frequently prescribed
diuretics, antithrombotics, lipid-lowering drugs, and antidiabetic
treatment. This group also had lower haemoglobin, and higher
serum ferritin and potassium levels. Importantly, there was no
significant difference in the use of beta-blockers and drugs acting
on the renin–angiotensin system.
The impact of ferric carboxymaltose
on renal function
In patients receiving FCM, a modest increase in eGFR from
baseline was detected throughout the whole study period, ..
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.. whereas patients in the placebo group demonstrated no sig-
nificant changes in eGFR from baseline during the follow-up
period (week 4, 2.61± 0.70 vs. 0.50± 0.99mL/min/1.73m2;
week 12, 1.60± 0.77 vs. –0.81±1.08mL/min/1.73m2; week 24,
2.64± 0.81 vs. –0.34± 1.1mL/min/1.73m2; FCM vs. placebo,
respectively; least squares means± SEs are shown). Treatment
with FCM was associated with a strong trend towards an increase
in eGFR at week 4 and 12, and a significant increase at week
24 with the following treatment effects: at week 4, 2.11±1.21
(P= 0.082); at week 12, 2.41± 1.33 (P= 0.070); and at week 24,
2.98±1.44mL/min/1.73m2 (P= 0.039) (Figure 1). This favourable
effect was seen in all pre-specified subgroups (P> 0.20 for interac-
tion including baseline renal function, age, sex, CHF severity and
aetiology, LVEF, presence of anaemia, diabetes mellitus, baseline
ferritin level, and body mass index) (Figure 2). In the sensitivity
analysis using the MDRD formula to calculate eGFR, we obtained
similar results. At week 4, treatment effect was 2.73± 1.444
(P= 0.059), at week 12, 2.82± 1.48 (P= 0.059), and at week 24,
3.91±1.65mL/min/1.73m2 (P= 0.019).
More patients in the FCM group demonstrated an improvement
in renal function. An increase in eGFR >3mL/min/1.73m2 at the
week 24 visit was 45% vs. 35%, FCM vs. placebo, respectively
(P= 0.0012; Figure 3). In the sensitivity analysis using a relative
cut-off level of 5% change from baseline eGFR value, at the week
24 visit deterioration in renal function (i.e. decline in eGFR >5%
of baseline eGFR) was present in 27% vs. 43%, and improvement
(i.e. increase in eGFR >5% of baseline eGFR) in 45% vs. 38%,
whereas no change was present in 27% vs. 20% (FCM vs. placebo,
respectively; P= 0.02).
Efficacy of ferric carboxymaltose
in relation to renal function
The original primary and secondary endpoints stratified by base-
line eGFR (preserved and impaired renal function) are presented
in Figure 4. There was no significant interaction between renal
function and the effects of FCM on the primary and secondary
endpoints.
Primary endpoints
At week 24, patients treated with FCM had improved NYHA class
(adjusted for baseline) compared with those receiving placebo (OR
2.30, 95% CI 1.23–4.28, P= 0.009; andOR 2.43, 95% CI 1.30–4.55,
P= 0.006, for patients with preserved and impaired renal function
at baseline, respectively; Figure 4A). Self-reported PGA ranks were
also better for patients receiving FCM vs. placebo (OR 2.41, 95% CI
1.48–3.95, P< 0.001; and OR 2.51, 95% CI 1.47–4.29, P< 0.001
for patients with preserved and impaired renal function at baseline,
respectively; Figure 4A).
Secondary endpoints
Compared with placebo, FCM significantly improved self-reported
PGA and NYHA class at weeks 4 and 12 in patients with preserved
and impaired renal function (Figure 4A). Significant improvements
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline demographics and clinical characteristics by renal function
Patients with
eGFR <60mL/min/1.73m2
(n= 203)
Patients with
eGFR ≥60mL/min/1.73m2
(n= 256)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 71.8 (9.17) 64.4 (10.55) <0.001
Female sex, n (%) 102 (50.25) 142 (55.47) 0.265
Caucasian, n (%) 202 (99.51) 256 (100.0) 0.261
NYHA class, n (%)
II 28 (13.79) 54 (21.09) 0.043
III 175 (86.21) 202 (78.91)
Left ventricular ejection fraction (%) 33.0 [30.00, 35.00] 33.0 [30.00, 35.00] 0.297
Body weight (kg) 76.0 [65.20, 85.00] 76.0 [67.50, 88.25] 0.455
Body mass index (kg/m2) 27.2 [25.40, 31.02] 27.5 [24.21, 31.25] 0.924
Blood pressure (mmHg)
Systolic 125.3 (15.80) 127.0 (13.80) 0.230
Diastolic 75.04 (10.26) 77.7 (8.75) 0.004
Pulse rate (b.p.m.) 70.0 [62.00, 78.00] 71.5 [64.00, 78.00] 0.096
Six-minute walk test distance (m) 265.0 [184.00, 334.00] 282.0 [204.00, 357.00] 0.048
Ischaemic cause of heart failure, n (%) 170 (83.74) 198 (77.34) 0.088
Cardiovascular risk factor
Hypertension (treated with drugs), n (%) 168 (82.76) 203 (79.30) 0.349
Dyslipidaemia (treated with drugs), n (%) 104 (51.23) 110 (42.97) 0.078
Diabetes mellitus, n (%) 72 (35.47) 58 (22.66) 0.003
History of atrial fibrillation, n (%) 66 (32.51) 72 (28.13) 0.309
Medical history
Myocardial infarction, n (%) 131 (64.53) 127 (49.61) 0.001
Angina pectoris, n (%) 111 (54.68) 149 (58.20) 0.449
Stroke, n (%) 18 (8.87) 15 (5.86) 0.215
Previous CABG, n (%) 30 (14.78) 17 (6.64) 0.004
Previous PTCA, n (%) 38 (18.72) 27 (10.55) 0.013
Previous coronary revascularization, n (%) 59 (29.06) 36 (14.06) <0.001
Laboratory measurements
Haemoglobin (g/L) 117.8 (12.36) 120.3 (13.38) 0.040
Mean corpuscular volume (fL) 92.3 (7.19) 91.1 (7.94) 0.096
Serum ferritin (μg/L) 44.0 [24.00, 77.00] 33.5 [16.00, 65.00] <0.001
Transferrin saturation (%) 15.6 [11.29, 21.37] 15.6 [9.93, 21.92] 0.513
C-reactive protein (mg/L) 2.9 [2.90, 6.00] 2.9 [2.90, 5.00] 0.002
Sodium (mmol/L) 141.0 [139.00, 142.00] 141.0 [139.00, 142.00] 0.253
Potassium (mmol/L) 4.6 [4.30, 5.10] 4.5 [4.20, 4.80] <0.001
Alanine aminotransferase (U/L) 17.0 [13.00, 20.00] 17.5 [14.00, 23.50] 0.030
Aspartate aminotransferase (U/L) 20.0 [17.00, 25.00] 21.0 [18.00, 25.00] 0.296
Creatinine (mg/dL) 1.4 [1.15, 1.70] 0.9 [0.79, 1.01] <0.001
eGFR (mL/min/1.73m2) 42.9 (12.35) 78.1 (12.82) -
Blood urea nitrogen (mg/dL) 29.0 [22.00, 40.00] 17.0 [14.00, 21.00] <0.001
Concomitant treatment
Diuretic, n (%) 194 (95.57) 226 (88.28) 0.005
Agents acting on the renin–angiotensin system, n (%) 182 (89.66) 240 (93.75) 0.110
Beta-blocker, n (%) 170 (83.74) 221 (86.33) 0.439
Cardiac glycosides, n (%) 30 (14.78) 41 (16.02) 0.716
Antithrombotic (including ASA), n (%) 170 (83.74) 187 (73.05) 0.006
Lipid-lowering, n (%) 116 (57.14) 98 (38.28) <0.001
Insulin, n (%) 26 (12.81) 10 (3.91) <0.001
Oral hypoglycaemic agents, n (%) 39 (19.21) 32 (12.50) 0.048
Data reported are the number (percentage) of patients for categorical data and mean (SD) or median [lower quartile, upper quartile] for continuous variables depending on
the distribution of the data.
P-values were obtained for continuous variables using either two-sample t-tests with Satterthwaite’s assumed unequal variances or the Kruskal–Wallis test depending on the
distribution of the data. For categorical variables, P-values were obtained using 𝜒2 tests.
ASA, acetylsalicylic acid; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; PTCA, percutaneous transluminal coronary angioplasty
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Impact of i.v. ferric carboxymaltose (FCM) treatment on renal function vs. placebo. Values are expressed as least squares means± SE.
eGFR, estimated glomerular filtration rate.
Figure 2 Treatment effect on renal function in pre-defined subgroups at week 24. Treatment effect was expressed as a continuous variable,
being the least squares means change from baseline±1 SE. BMI, body mass index; eGFR, estimated glomerular filtration rate; Hb, haemoglobin;
HF, heart failure.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Impact of i.v. ferric carboxymaltose (FCM) on renal function categorized by change in estimated glomerular filtration rate (eGFR;
mL/min/1.73m2) at week 24. Data were available for 347 patients with a change in eGFR at week 24 (106 patients in the placebo group and
241 patients in the FCM group).
were also seen in 6min walk test distance and quality of life
assessments by EQ-5D and KCCQ at weeks 4, 12, and 24 in
patients with preserved and impaired renal function (Figure 4B).
Safety of ferric carboxymaltose
in relation to renal function
Safety endpoints and main investigator-reported adverse events are
listed in Table 2.
During the study period, there were 8 (3.9%) deaths in patients
with impaired renal function (3 in the placebo group and 5 in
the FCM group, P=1.00), whereas only 1 (0.4%) patient with
preserved renal function died (in the placebo group).
In patients with impaired renal function, the FCM group com-
pared with the placebo group experienced a trend toward lower
incidence rate of first events for hospitalizations [HR 0.62, 95%
CI 0.30–1.31, P= 0.21], which mainly resulted from a significantly
lower incidence of first cardiovascular hospitalization (HR 0.36,
95% CI 0.15–0.87, P= 0.02). In these patients, the HR (FCM com-
pared with placebo) for the time to first event for either any death
or cardiovascular hospitalization was 0.53 (95% CI 0.25–1.14,
P= 0.11).
In patients with preserved renal function, the incidence rates of
both first all-cause hospitalizations and first cardiovascular hospi-
talizations were similar between the treatment groups, P= 0.82 and
P= 0.55, respectively.
Patients with impaired renal function who were administered
FCM experienced fewer cardiac disorders compared with those
receiving placebo (HR 0.44, 95%CI 0.24–0.83, P= 0.01). In patients
with preserved renal function, the rates of investigator-reported .
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.. cardiac adverse events were similar in both treatment groups
(P= 0.47).
During the study period, study treatment was stopped prema-
turely in 12 (5.9%) patients with impaired renal function [7 (5.4%)
in the FCM group and 5 (6.8%) in the placebo group, P= 0.76] and
in 18 (7%) patients with preserved renal function [9 (5.2%) in the
FCM group and 9 (10.7%) in the placebo group; P= 0.12].
Discussion
There are two novel findings of this further analysis of the FAIR-HF
study. Treatment with FCM for 24 weeks in ID patients with CHF
is associated with modest improvement in renal function as evi-
denced by an increase in eGFR. This favourable effect is seen across
the whole clinical spectrum of the disease. Additionally, there was
no interaction between baseline renal function and the clinical
benefits of FCM, which suggests that FCM is equally effective in
patients with preserved and impaired renal function. Importantly,
the overall safety and adverse event profiles of FCM were simi-
lar in these two groups. Interestingly, in patients with renal dys-
function, those treated with FCM had fewer hospitalizations for
any cardiovascular reason and experienced cardiac disorders less
frequently.
Renal dysfunction is a frequent co-morbidity in CHF that exerts
an adverse effect on the cardiovascular system leading to a pro-
gression of the disease, and impaired renal function constitutes one
of the strongest predictors of poor clinical outcomes in CHF.1,2,33
Interestingly, virtually none of the currently applied CHF thera-
pies efficiently prevent deterioration in renal function.3,34 It seems
that renoprotection may constitute a desirable feature of novel
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Primary (A) and secondary (B) endpoints of the FAIR-HF trials stratified by baseline estimated glomerular filtration rate (eGFR;
mL/min/1.73m2). FCM, ferric carboxymaltose.
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Table 2 Safety endpoints and investigator-reported adverse events by baseline renal function
Patients with eGFR <60mL/min/
1.73m2 (n= 203)
No. of patients with endpoint or event
(incidence/100 patient-years at risk)
Patients with eGFR ≥60mL/
min/1.73m2 (n= 256)
No. of patients with endpoint or event
(incidence/100 patient-years at risk)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo
(n= 73)
FCM
(n=130)
HR (95% CI) P-value Placebo
(n= 81)
FCM
(n=175)
HR
(95% CI)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Safety endpoints
Death 3 (8.9) 5 (8.1) 0.91 (0.22–3.79) 0.89 1 (2.5) 0 (0.0) – –
Cardiovascular death 3 (8.9) 4 (6.5) 0.72 (0.16–3.24) 0.67 1 (2.5) 0 (0.0) – –
Death due to worsening CHF 3 (8.9) 0 (0.0) – – 0 (0.0) 0 (0.0) – –
First hospitalization 13 (42.9) 15 (25.9) 0.62 (0.30–1.31) 0.21 4 (10.4) 10 (12.0) 1.14 (0.36–3.65) 0.82
Hospitalization for any cardiovascular reason 12 (39.0) 8 (13.4) 0.36 (0.15–0.87) 0.02 2 (5.1) 7 (8.3) 1.62 (0.34–7.79) 0.55
First hospitalization for worsening CHF 6 (18.4) 4 (6.6) 0.36 (0.10–1.26) 0.11 1 (2.5) 2 (2.3) 0.92 (0.08–10.09) 0.94
Any hospitalization or death 14 (46.2) 20 (34.5) 0.76 (0.39–1.51) 0.44 5 (13.1) 10 (12.0) 0.92 (0.31–2.68) 0.87
Hospitalization for any cardiovascular reason or death 13 (42.2) 13 (21.8) 0.53 (0.25–1.14) 0.11 3 (7.7) 7 (8.3) 1.08 (0.28–4.18) 0.91
Hospitalization for worsening CHF or death 8 (24.6) 9 (14.8) 0.60 (0.23–1.56) 0.29 2 (5.1) 2 (2.3) 0.46 (0.06–3.27) 0.44
Investigator-reported adverse events
Cardiac disorders 21 (72.8) 18 (31.5) 0.44 (0.24–0.83) 0.01 12 (32.5) 20 (24.9) 0.77 (0.38–1.57) 0.47
Gastrointestinal disorders 1 (3.0) 11 (18.8) 6.34 (0.82–49.14) 0.08 4 (10.4) 13 (15.6) 1.49 (0.49–4.58) 0.48
General disorders and administration site conditions 2 (6.0) 15 (25.8) 4.25 (0.97–18.58) 0.06 4 (10.3) 8 (9.5) 0.93 (0.28–3.08) 0.90
Infections and infestations 10 (32.0) 19 (33.7) 1.00 (0.46–2.16) 1.00 14 (39.2) 31 (39.4) 1.00 (0.53–1.88) 1.00
Abnormal lab test, vital sign, or physical finding 4 (12.1) 15 (26.3) 2.14 (0.71–6.44) 0.18 6 (15.6) 17 (20.7) 1.33 (0.52–3.38) 0.55
Respiratory, thoracic, and mediastinal disorders 5 (15.3) 4 (6.6) 0.43 (0.11–1.59) 0.21 5 (13.2) 5 (5.9) 0.45 (0.13–1.55) 0.21
Vascular disorders 2 (6.0) 10 (16.9) 3.06 (0.67–14.04) 0.15 9 (24.6) 10 (12.0) 0.49 (0.20–1.20) 0.12
P-value: comparison between placebo and FCM.
P-values were obtained using Wald tests via Cox proportional hazard models.
Patient-years for each person were calculated using the formula [min(event date, safety censor date) – start date]/365.25. Values were then summed for each group.
CHF, chronic heart failure; CI, confidence interval; FCM, ferric carboxymaltose; HR, hazard ratio.
treatments in CHF potentially to improve clinical outcome; this,
however, has not been yet tested/confirmed in clinical trials.
In chronic diseases, ID has been traditionally linked with
anaemia.35 Only recently has it been recognized that patients with
CHF are prone to develop ID irrespective of anaemia, and ID
has multifaceted clinical consequences related to poor outcome,
exercise intolerance, and impaired quality of life.11–15 It appears
that i.v. iron supplementation in CHF patients with ID improves
symptoms, functional capacity, and quality of life, with a favourable
safety profile irrespective of co-existing anaemia.8,16–18,36 Taking
into account the role iron plays in cellular energetics, it is pru-
dent to state that the maintenance of iron homeostasis is partic-
ularly important not only for erythropoiesis but also for cells and
organs characterized by intensive oxidative metabolism and high
energy demand, including the kidney.20,21 Thus, it may be hypoth-
esized that repletion of iron in CHF patients may ultimately result
in long-term stabilization or even improvement of renal function.
On the other hand, it needs to be remembered that iron may also
induce oxidative stress, mainly via involvement in the production of
reactive oxygen and nitrogen species, and its pro-oxidative prop-
erties potentially may have deleterious effects on renal structure
and function.22,37–40 Thus, the safety of iron therapy needs to be
clearly addressed in CHF patients, who potentially may also be
prone to deterioration in renal function as part of the cardio-renal
syndrome, particularly during long-term i.v. iron supplementation.
The results of our study confirm that 24 week therapy with i.v.
FCM modestly improves renal function in addition to other clini-
cal benefits. To the best of our knowledge, this is the largest study
showing evidence that a drug with a positive effect on functional .
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. status and quality of life in CHF patients also exerts favourable
effects on renal function. Overall, among therapies applied in CHF,
only implantation of a ventricular assist device leads to improve-
ment in renal function,41 whereas studies with other therapies
(including digoxin and resynchronization therapy) provided con-
flicting data.42,43 In the context of i.v. iron supplementation, only
Toblli et al.8 demonstrated that in anaemic CHF patients with ID
and renal dysfunction, 5 week therapy with i.v. iron sucrose resulted
in significant improvement in renal function as evidenced by an
increase in creatinine clearance. However, this was a comparatively
small study with only 40 patients, half of which received active
treatment for a short period of time. Our study extends these
preliminary observations to a much broader CHF population, as
we have demonstrated improvement in renal function irrespective
of baseline haemoglobin level and renal function.
The results of this analysis deserve broader interpretation in
the context of the chosen renal endpoints. We have prospectively
decided to use changes in eGFR as a safety endpoint in order to
evaluate the effect of FCM therapy on renal function. Estimated
GFR has already been widely accepted as a marker of renal
function in clinical studies,29,44 and a decline in eGFR is closely
linked to poor clinical outcomes.2,33 This concept is based on
the assumption that the GFR indicates both the number of active
nephrons in the kidney and the average filtration capacity of each
nephron.45 Thus, changes in GFR may reflect either progression
(theoretically also remission) of kidney disease or haemodynamic
changes affecting the filtration rate.45 In some clinical studies,
effects on GFR detected shortly after initiation of therapy were
related to haemodynamic effects, whereas long-term changes were
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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linked to direct effects on the kidney.45,46 In our study, an increase in
eGFR was detectable after just 4 weeks of therapy, which seems to
be due to an improvement in compromised renal haemodynamics
rather than to any direct effects on the nephrons. As we have not
evaluated haemodynamic indices during the study, this remains a
speculative interpretation; on the other hand, there is evidence that
i.v. iron may improve LVEF and decrease serum levels of natriuretic
peptide, indicating potentially favourable haemodynamic effects in
CHF patients.8 Subsequent steady levels of eGFR observed from
week 12 to week 24 suggest stabilization of renal function with
no worrying evidence of detrimental effects of long-term i.v. iron
therapy (i.e. beyond 4 weeks). Previous studies in anaemic CKD
patients show either no relevant changes or a small decline in
GFR after i.v. iron supplementation.7,47,48 This is not necessarily
contradictory to our results. In contrast to CKD, impaired GFR
in CHF seems to be predominantly due to multiple haemodynamic
changes (including impaired perfusion or/and venous congestion).
Consequently, viable nephrons may be able to maintain their
filtration capabilities, and therefore GFR has the potential to be
improved. This interpretation, however, needs confirmation in
clinical studies.
In this analysis, we used the CKD–EPI formula to calculate the
eGFR as it is robust and accurate across a wide range of kidney
function, being currently recommended particularly in patients
with systolic CHF.27,29 This surrogate approach does not allow the
measurement of ‘real’ renal function, and for precise quantitative
assessment of GFR nuclear isotope estimates should be applied.
As these methods are laborious and require special equipment,
they are not suitable for large clinical trials. To overcome such
difficulties, creatinine-based formulas to estimate GFR have been
proposed and validated in different clinical populations.2,25,27,44
The evidence of equal clinical efficacy and safety of FCM therapy
in CHF patients with renal impairment is of relevance. In clinical
practice, these patients are often deprived of effective CHF treat-
ment, being perceived as potentially more prone to side effects
with less evidence of benefit. In fact, recent analyses from large
clinical trials showed life-saving treatments with ACE inhibitors,49
beta-blockers,50,51 or resynchronization therapy42 to be effective
regardless of baseline renal function. Our results confirm that this
is also the case for i.v. iron supplementation in CHF patients with
ID. Of interest, patients with renal impairment receiving FCM may
have experienced a lower incidence rate of first cardiovascular hos-
pitalization and fewer cardiac disorders. These intriguing results
need to be confirmed in larger studies.
Limitations
The main limitation is the use of eGFR as a renal endpoint, which
is only an indirect estimate of renal function with certain limi-
tations in comparison with direct measures. We are aware that
we have not evaluated the effects of FCM on creatinine produc-
tion/excretion and non-renal clearance, all of which may potentially
affect the eGFR calculation (being based on creatinine change). As
originally planned, we have also performed the same analyses using
the six-variable MDRD formula, finding no difference in the inter-
pretation of the results. However, we are fully aware that additional ..
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.. studies with endpoints precisely evaluating multiple aspects of com-
plex renal function are needed to confirm renoprotective effects of
FCM therapy. Such studies are also required in order to understand
the biological mechanisms underlying potential beneficial effects of
iron replacement therapy in CHF, which are not addressed in this
analysis. In particular, it would be clinically relevant to distinguish
between haemodynamic and peripheral effects of i.v. iron therapy in
CHF. In this context, it would be interesting to evaluate the effects
of FCM on biomarkers reflecting tubular function, as they are true
energy consumers in the kidneys.
In conclusion, correction of ID in CHF patients with i.v. FCM
is associated with a modest, but significant improvement in renal
function, seen across all the pre-specified subgroups. FCM therapy
was effective in CHF patients with renal dysfunction and had a
favourable safety profile.
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